Sameer Dani - Academia.edu (original) (raw)

Papers by Sameer Dani

Research paper thumbnail of CRT-100.84 Long-term Clinical Outcomes After the Treatment of Coronary Stenosis With Sirolimus-coated Balloon Angioplasty: Results From NANOLUTE Real-World Registry

JACC: Cardiovascular Interventions, 2018

Research paper thumbnail of CRT-100.74 Safety And Efficacy Of Sirolimus-Coated Balloon In Diabetic Patients With Coronary Stenosis: Subgroup Analysis From NANOLUTE Study

JACC: Cardiovascular Interventions, 2018

year was assessed and proportional Cox hazard model analyses were performed to assess outcome aft... more year was assessed and proportional Cox hazard model analyses were performed to assess outcome after adjustment for confounding factors (i.e., presentation with acute myocardial infarction (MI), diabetes, hypertension, history of coronary artery disease, smoking, presentation in cardiogenic shock (CS) and age). RESULTS Average age was 65.3 +/-11.5. The 1-year unadjusted death rate was 5.4% in WM, 8.8% in BM, 9.6% in WW, and 9.3% in BW. After adjustment for cardiovascular risk factors and presentation with acute MI and CS,WM had the best outcomes compared to the other groups (in particular, BM had worse outcomes compared to WM and WW worse outcomes compared to WM). There was no gender difference among the black population and no race difference among white or black women (Figure). There was a significant interaction between gender and race (p¼0.002). CONCLUSIONS In this large cohort of patients with coronary artery disease undergoing PCI, we observed significant race and sex disparities in outcomes even after adjustment for clinical presentation and cardiovascular risk factors.

Research paper thumbnail of CRT-100.83 An All-comer Ongoing en-ABL Registry With a Novel Abluminal Coated Sirolimus-eluting Stent: Two-year Clinical Outcomes in Patients With Complex Lesions

JACC: Cardiovascular Interventions, Feb 1, 2018

mean age was 67.2 years. The Caucasian patients (n¼2637, 65%) were significantly older, had a low... more mean age was 67.2 years. The Caucasian patients (n¼2637, 65%) were significantly older, had a lower baseline creatinine, and lower rates of hypertension and diabetes compared to the non-Caucasian patients. Information on creatinine at 3 days was available on 1923 patients and on creatinine at 3 months on 3106 patients. CIN occurred in 92 (7.13%) Caucasian patients (n¼1291 patients) and in 42 (6.65%) non-Caucasians at 72 hours after the procedure (odds ratio [OR] 1.08, 95% confidence interval [CI] 0.74-1.57; P¼0.69). At 3 months, renal dysfunction was seen in 231 (11.24%) Caucasian patients (n¼2056) versus 121 (11.52%) of the non-Caucasian group (OR 0.97, CI 0.77-1.23; P¼0.81). After a follow-up of 5 years, of the 4070 patients, 17 patients (0.64%) of the Caucasian group were placed on dialysis versus 27 (1.88 %) of the non-Caucasian group (OR 0.34, 0.18-0.62; P¼0.0004) and 622 (23.59%) of the Caucasian patients had died compared to 335 (23.38%) of the non-Caucasian group (OR¼1.01, 95% CI 0.87-1.18; P¼0.88). CONCLUSIONS In this cohort of patients, race was not associated with the development of CIN at 72 hours, or the development of renal dysfunction at 3 months post angiography or intervention. In the long term, the rate of initiation of dialysis was significantly lower in the Caucasian patients but mortality was not.

Research paper thumbnail of P6074Clinical outcomes following the treatment of sirolimus coated balloon in coronary artery stenosis in real world population: results from nanolute registry

European Heart Journal, Aug 1, 2017

Further investigation is warranted to assess whether this strategy is associated with improved gr... more Further investigation is warranted to assess whether this strategy is associated with improved graft survival.

Research paper thumbnail of Consensus document: management of heart failure in type 2 diabetes mellitus

Heart Failure Reviews, 2020

Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growin... more Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growing burden of these two conditions and their impact on health of the individual and on society in general needs urgent attention from the health care professionals. Availability of multiple treatment choices for managing T2DM and HF may make therapeutic decisions more complex for clinicians. Recent cardiovascular outcome trials of antidiabetic drugs have added very robust evidence to effectively manage subjects with this dual condition. This consensus statement provides the prevalence trends and the impact of this dual burden on patients. In addition, it concisely narrates the types of HF, the different treatment algorithms, and recommendations for physicians to comprehensively manage such patients.

Research paper thumbnail of TCT-263 To Assess the Safety and Efficacy of Novel Drug-Coated Balloon in All Comers, Real-World Population

Journal of the American College of Cardiology, 2019

Research paper thumbnail of TCT-264 Clinical Outcome Post–Sirolimus-Coated Balloon Angioplasty in Patients With De Novo Lesions Located in Small-Vessel Arteries (≤2.75 mm): 2-Year Results From a Prospective Study

Journal of the American College of Cardiology, 2019

Research paper thumbnail of TCTAP A-082 Sirolimus Coated Balloon: Long Term Results from NANOLUTE Real World Study

Journal of the American College of Cardiology, 2018

Research paper thumbnail of TCTAP A-071 Sirolimus Coated Balloon Angioplasty for In-stent Restenosis in Small Coronary Arteries

Journal of the American College of Cardiology, 2018

on reducing radiation exposure in patients received percutaneous coronary intervention patients. ... more on reducing radiation exposure in patients received percutaneous coronary intervention patients. METHODS Since Jan 2016, we organized a multidisciplinary team, including interventional cardiologists, dermatologist, intensivists, radiation technicians and nursing staffs. The patients, from 2 hospitals with cardiac catherization lab, were divided into 3 groups: stage 1 (n¼64) from March to November 2016, stage 2 (n¼42) from December 2016 to January 2017 and stage 3 (n¼62) from February to August 2017. The key interventions include reduce the frame rate of fluoroscopy with 15 frames/seconds instead of conventional 30 frames/seconds, reduce frame rate of video recording with 7.5 frames/seconds instead of conventional 15 frames/seconds, a guideline for radiation protection and innovative head, eye and neck protection device. A P-value less than 0.05 was considered statistically significant. RESULTS There is no difference among three study groups in baseline characteristic. The eye radiation dose of patients improved from 4.5 AE 3.9 mSV in stage 1, to 2.2 AE 2.4 in stage 2 and 0.6 AE 0.6 mSV in stage 3 (p<0.001). The neck radiation dose of patients reduced from 22.2 AE 39.1 mSV in stage 1, to 8.1 AE 8.6 in stage 2 and 3.3 AE 3.1 mSV in stage 3 (p<0.001). The back radiation dose of patients reduced from 183.8 AE 286.3 mSV in stage 1, to 39.2 AE 49.8 in stage 2 and 47.2.5 AE 44.3 mSV in stage 3 (p<0.001). The radiation dose of doctors reduced from 2.0AE1.4 mSV in stage 1, to 1.1 AE 1.3 in stage 2 and 1.2 AE 0.7 mSV in stage 3 (p¼0.001).

Research paper thumbnail of TCTAP A-039 Safety and Efficacy of Sirolimus Coated Balloon for the Treatment Coronary In-stent Restenosis: Results from Real World Multicenter Study

Journal of the American College of Cardiology, 2017

CONCLUSION In conclusion, aortic arch calcification from chest x-ray examination in patients with... more CONCLUSION In conclusion, aortic arch calcification from chest x-ray examination in patients with ACS provides valuable prognostic information on clinical outcomes. Studies with larger patient numbers would be needed to confirm this observation and delineate the detail picture of clinical outcomes in 4 AAC grade groups. Different principles of management for ACS patients with aortic arch calcification might also be needed and tested in subsequent studies.

Research paper thumbnail of Intensive dose of rosuvastatin (40 mg/day), initiated early and continued for 12 weeks, in ‘very high’ risk or ‘high’ risk Indian patients

Indian Heart Journal, 2014

The aim of the present study was to assess the short term prognostic significance of N-terminal p... more The aim of the present study was to assess the short term prognostic significance of N-terminal pro BNP (NT-proBNP), i n d i a n h e a r t j o u r n a l 6 6 (2 0 1 4) s 1 es 1 4 3

Research paper thumbnail of Transfemoral extraction of knotted pulmonary artery catheter in right atrium

Annals of cardiac anaesthesia, 1999

Knotting of a pulmonary artery catheter (PAC) is a rare complication which is usually seen to occ... more Knotting of a pulmonary artery catheter (PAC) is a rare complication which is usually seen to occur in the right ventricle. We describe knotting of a PAC in the right atrium and its extraction by non surgical means through the femoral route.

Research paper thumbnail of Technical Insights on Drug-Coated Balloons II

Drug-Coated Balloons, 2019

The drug-coated balloon is a future treatment device which leaves nothing behind. It delivers the... more The drug-coated balloon is a future treatment device which leaves nothing behind. It delivers the drug in a very short time and provides long-term release of the drug to treat posttreatment shortcomings. Currently paclitaxel and sirolimus are the only choices for drug-coated balloons. Preclinical study findings on paclitaxel are mixed and depend on various factors such as the drug carrier, balloon surface, drug size, coating method etc. The sirolimus-coated balloon is an emerging device and based on certain preclinical reports, it has generated new hope for safe and effective drug delivery.

Research paper thumbnail of Percutaneous transvenous mitral commissurotomy using inoue balloon catheter: A left femoral vein approach

Catheterization and Cardiovascular Diagnosis, 1995

ABSTRACT

Research paper thumbnail of TCT-588 Primary results of 2 years clinical investigation from en-ABL e-registry using novel abluminal coated sirolimus eluting stent with bio-degradable polymer matrix

Journal of the American College of Cardiology, 2015

Research paper thumbnail of Correlation Between Ambulatory Blood Pressure Monitoring and Office Blood Pressure Measurement in Patients with Hypertension: A Community Study

The American Journal of the Medical Sciences

Research paper thumbnail of TCT CONNECT-253 3-Year Outcomes of Sirolimus-Coated Balloon Treatment in De Novo and In-Stent Restenotic Coronary Lesions

Journal of the American College of Cardiology

Research paper thumbnail of TCT CONNECT-255 Long-Term Outcome After Coronary Revascularization With Sirolimus-Coated Balloon in Patients With Small-Vessel Disease (≤2.75 mm): 3-Year Results From NANOLUTE Real-World Study

Journal of the American College of Cardiology

Research paper thumbnail of Self-blood pressure measurement as compared to office blood pressure measurement in a large Indian population; the India Heart Study

Research paper thumbnail of A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanoluté Registry

Cardiovascular Revascularization Medicine

Research paper thumbnail of CRT-100.84 Long-term Clinical Outcomes After the Treatment of Coronary Stenosis With Sirolimus-coated Balloon Angioplasty: Results From NANOLUTE Real-World Registry

JACC: Cardiovascular Interventions, 2018

Research paper thumbnail of CRT-100.74 Safety And Efficacy Of Sirolimus-Coated Balloon In Diabetic Patients With Coronary Stenosis: Subgroup Analysis From NANOLUTE Study

JACC: Cardiovascular Interventions, 2018

year was assessed and proportional Cox hazard model analyses were performed to assess outcome aft... more year was assessed and proportional Cox hazard model analyses were performed to assess outcome after adjustment for confounding factors (i.e., presentation with acute myocardial infarction (MI), diabetes, hypertension, history of coronary artery disease, smoking, presentation in cardiogenic shock (CS) and age). RESULTS Average age was 65.3 +/-11.5. The 1-year unadjusted death rate was 5.4% in WM, 8.8% in BM, 9.6% in WW, and 9.3% in BW. After adjustment for cardiovascular risk factors and presentation with acute MI and CS,WM had the best outcomes compared to the other groups (in particular, BM had worse outcomes compared to WM and WW worse outcomes compared to WM). There was no gender difference among the black population and no race difference among white or black women (Figure). There was a significant interaction between gender and race (p¼0.002). CONCLUSIONS In this large cohort of patients with coronary artery disease undergoing PCI, we observed significant race and sex disparities in outcomes even after adjustment for clinical presentation and cardiovascular risk factors.

Research paper thumbnail of CRT-100.83 An All-comer Ongoing en-ABL Registry With a Novel Abluminal Coated Sirolimus-eluting Stent: Two-year Clinical Outcomes in Patients With Complex Lesions

JACC: Cardiovascular Interventions, Feb 1, 2018

mean age was 67.2 years. The Caucasian patients (n¼2637, 65%) were significantly older, had a low... more mean age was 67.2 years. The Caucasian patients (n¼2637, 65%) were significantly older, had a lower baseline creatinine, and lower rates of hypertension and diabetes compared to the non-Caucasian patients. Information on creatinine at 3 days was available on 1923 patients and on creatinine at 3 months on 3106 patients. CIN occurred in 92 (7.13%) Caucasian patients (n¼1291 patients) and in 42 (6.65%) non-Caucasians at 72 hours after the procedure (odds ratio [OR] 1.08, 95% confidence interval [CI] 0.74-1.57; P¼0.69). At 3 months, renal dysfunction was seen in 231 (11.24%) Caucasian patients (n¼2056) versus 121 (11.52%) of the non-Caucasian group (OR 0.97, CI 0.77-1.23; P¼0.81). After a follow-up of 5 years, of the 4070 patients, 17 patients (0.64%) of the Caucasian group were placed on dialysis versus 27 (1.88 %) of the non-Caucasian group (OR 0.34, 0.18-0.62; P¼0.0004) and 622 (23.59%) of the Caucasian patients had died compared to 335 (23.38%) of the non-Caucasian group (OR¼1.01, 95% CI 0.87-1.18; P¼0.88). CONCLUSIONS In this cohort of patients, race was not associated with the development of CIN at 72 hours, or the development of renal dysfunction at 3 months post angiography or intervention. In the long term, the rate of initiation of dialysis was significantly lower in the Caucasian patients but mortality was not.

Research paper thumbnail of P6074Clinical outcomes following the treatment of sirolimus coated balloon in coronary artery stenosis in real world population: results from nanolute registry

European Heart Journal, Aug 1, 2017

Further investigation is warranted to assess whether this strategy is associated with improved gr... more Further investigation is warranted to assess whether this strategy is associated with improved graft survival.

Research paper thumbnail of Consensus document: management of heart failure in type 2 diabetes mellitus

Heart Failure Reviews, 2020

Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growin... more Type 2 diabetes mellitus (T2DM) is a known predisposing factor for heart failure (HF). The growing burden of these two conditions and their impact on health of the individual and on society in general needs urgent attention from the health care professionals. Availability of multiple treatment choices for managing T2DM and HF may make therapeutic decisions more complex for clinicians. Recent cardiovascular outcome trials of antidiabetic drugs have added very robust evidence to effectively manage subjects with this dual condition. This consensus statement provides the prevalence trends and the impact of this dual burden on patients. In addition, it concisely narrates the types of HF, the different treatment algorithms, and recommendations for physicians to comprehensively manage such patients.

Research paper thumbnail of TCT-263 To Assess the Safety and Efficacy of Novel Drug-Coated Balloon in All Comers, Real-World Population

Journal of the American College of Cardiology, 2019

Research paper thumbnail of TCT-264 Clinical Outcome Post–Sirolimus-Coated Balloon Angioplasty in Patients With De Novo Lesions Located in Small-Vessel Arteries (≤2.75 mm): 2-Year Results From a Prospective Study

Journal of the American College of Cardiology, 2019

Research paper thumbnail of TCTAP A-082 Sirolimus Coated Balloon: Long Term Results from NANOLUTE Real World Study

Journal of the American College of Cardiology, 2018

Research paper thumbnail of TCTAP A-071 Sirolimus Coated Balloon Angioplasty for In-stent Restenosis in Small Coronary Arteries

Journal of the American College of Cardiology, 2018

on reducing radiation exposure in patients received percutaneous coronary intervention patients. ... more on reducing radiation exposure in patients received percutaneous coronary intervention patients. METHODS Since Jan 2016, we organized a multidisciplinary team, including interventional cardiologists, dermatologist, intensivists, radiation technicians and nursing staffs. The patients, from 2 hospitals with cardiac catherization lab, were divided into 3 groups: stage 1 (n¼64) from March to November 2016, stage 2 (n¼42) from December 2016 to January 2017 and stage 3 (n¼62) from February to August 2017. The key interventions include reduce the frame rate of fluoroscopy with 15 frames/seconds instead of conventional 30 frames/seconds, reduce frame rate of video recording with 7.5 frames/seconds instead of conventional 15 frames/seconds, a guideline for radiation protection and innovative head, eye and neck protection device. A P-value less than 0.05 was considered statistically significant. RESULTS There is no difference among three study groups in baseline characteristic. The eye radiation dose of patients improved from 4.5 AE 3.9 mSV in stage 1, to 2.2 AE 2.4 in stage 2 and 0.6 AE 0.6 mSV in stage 3 (p<0.001). The neck radiation dose of patients reduced from 22.2 AE 39.1 mSV in stage 1, to 8.1 AE 8.6 in stage 2 and 3.3 AE 3.1 mSV in stage 3 (p<0.001). The back radiation dose of patients reduced from 183.8 AE 286.3 mSV in stage 1, to 39.2 AE 49.8 in stage 2 and 47.2.5 AE 44.3 mSV in stage 3 (p<0.001). The radiation dose of doctors reduced from 2.0AE1.4 mSV in stage 1, to 1.1 AE 1.3 in stage 2 and 1.2 AE 0.7 mSV in stage 3 (p¼0.001).

Research paper thumbnail of TCTAP A-039 Safety and Efficacy of Sirolimus Coated Balloon for the Treatment Coronary In-stent Restenosis: Results from Real World Multicenter Study

Journal of the American College of Cardiology, 2017

CONCLUSION In conclusion, aortic arch calcification from chest x-ray examination in patients with... more CONCLUSION In conclusion, aortic arch calcification from chest x-ray examination in patients with ACS provides valuable prognostic information on clinical outcomes. Studies with larger patient numbers would be needed to confirm this observation and delineate the detail picture of clinical outcomes in 4 AAC grade groups. Different principles of management for ACS patients with aortic arch calcification might also be needed and tested in subsequent studies.

Research paper thumbnail of Intensive dose of rosuvastatin (40 mg/day), initiated early and continued for 12 weeks, in ‘very high’ risk or ‘high’ risk Indian patients

Indian Heart Journal, 2014

The aim of the present study was to assess the short term prognostic significance of N-terminal p... more The aim of the present study was to assess the short term prognostic significance of N-terminal pro BNP (NT-proBNP), i n d i a n h e a r t j o u r n a l 6 6 (2 0 1 4) s 1 es 1 4 3

Research paper thumbnail of Transfemoral extraction of knotted pulmonary artery catheter in right atrium

Annals of cardiac anaesthesia, 1999

Knotting of a pulmonary artery catheter (PAC) is a rare complication which is usually seen to occ... more Knotting of a pulmonary artery catheter (PAC) is a rare complication which is usually seen to occur in the right ventricle. We describe knotting of a PAC in the right atrium and its extraction by non surgical means through the femoral route.

Research paper thumbnail of Technical Insights on Drug-Coated Balloons II

Drug-Coated Balloons, 2019

The drug-coated balloon is a future treatment device which leaves nothing behind. It delivers the... more The drug-coated balloon is a future treatment device which leaves nothing behind. It delivers the drug in a very short time and provides long-term release of the drug to treat posttreatment shortcomings. Currently paclitaxel and sirolimus are the only choices for drug-coated balloons. Preclinical study findings on paclitaxel are mixed and depend on various factors such as the drug carrier, balloon surface, drug size, coating method etc. The sirolimus-coated balloon is an emerging device and based on certain preclinical reports, it has generated new hope for safe and effective drug delivery.

Research paper thumbnail of Percutaneous transvenous mitral commissurotomy using inoue balloon catheter: A left femoral vein approach

Catheterization and Cardiovascular Diagnosis, 1995

ABSTRACT

Research paper thumbnail of TCT-588 Primary results of 2 years clinical investigation from en-ABL e-registry using novel abluminal coated sirolimus eluting stent with bio-degradable polymer matrix

Journal of the American College of Cardiology, 2015

Research paper thumbnail of Correlation Between Ambulatory Blood Pressure Monitoring and Office Blood Pressure Measurement in Patients with Hypertension: A Community Study

The American Journal of the Medical Sciences

Research paper thumbnail of TCT CONNECT-253 3-Year Outcomes of Sirolimus-Coated Balloon Treatment in De Novo and In-Stent Restenotic Coronary Lesions

Journal of the American College of Cardiology

Research paper thumbnail of TCT CONNECT-255 Long-Term Outcome After Coronary Revascularization With Sirolimus-Coated Balloon in Patients With Small-Vessel Disease (≤2.75 mm): 3-Year Results From NANOLUTE Real-World Study

Journal of the American College of Cardiology

Research paper thumbnail of Self-blood pressure measurement as compared to office blood pressure measurement in a large Indian population; the India Heart Study

Research paper thumbnail of A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanoluté Registry

Cardiovascular Revascularization Medicine